GLP-1 Market
LLY $1136.11 ▼ -0.2% NVO $42.53 ▼ -2.1% PFE $27.55 ▼ -0.6% VKTX $29.95 ▼ -5.0% KLRA $13.45 ▼ -2.2% GPCR $38.95 ▲ +1.3% RHHBY $54.90 ▲ +0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Semaglutide (Wegovy)

Company
The Methodist Hospital Research Institute
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
11 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

11 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for Semaglutide (Wegovy) and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05819853

    Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

    Not yet reported University of Colorado, Denver 80 participants Est. completion 2028-06-30 1 site
    Other conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
    View official trial listing →
  • Recruiting NCT NCT06374875

    Fibrosis Lessens After Metabolic Surgery

    Not yet reported The Cleveland Clinic 120 participants Est. completion 2029-12-31 22 sites
    MASLDMASH Other conditions: Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, Obesity
    View official trial listing →
  • Recruiting NCT NCT06751589

    A Study of a Weight Loss Intervention in People With Endometrial Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 36 participants Est. completion 2027-12 7 sites
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Recruiting NCT NCT06852391

    JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

    Not yet reported McMaster University 74 participants Est. completion 2027-12-31 1 site
    Other conditions: Obesity (Disorder)
    View official trial listing →
  • Recruiting NCT NCT07136714

    Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity

    Not yet reported Nordsjaellands Hospital 116 participants Est. completion 2027-09 1 site
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Recruiting NCT NCT07150975

    Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

    Not yet reported Gan & Lee Pharmaceuticals. 420 participants Est. completion 2027-06-30 1 site
    Other conditions: Obesity/Overweight in Adult
    View official trial listing →
  • Recruiting NCT NCT07204249

    Glutide for Ending Methamphetamine

    Not yet reported San Francisco Department of Public Health 162 participants Est. completion 2030-02-15 1 site
    Other conditions: Methamphetamine-dependence
    View official trial listing →
  • Recruiting NCT NCT07213466

    Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

    Not yet reported Mayo Clinic 100 participants Est. completion 2029-02-01 1 site
    Other conditions: Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
    View official trial listing →
  • Recruiting NCT NCT07275697

    Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

    Not yet reported Emma Svennberg 200 participants Est. completion 2028-12-30 1 site
    Other conditions: Atrial Fibrillation (AF), Obesity & Overweight
    View official trial listing →
  • Recruiting NCT NCT07523633

    Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

    Not yet reported Anders Fink-Jensen, MD, DMSci 100 participants Est. completion 2028-04-30 1 site
    Other conditions: Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence, Cannabis Addiction
    View official trial listing →
  • Recruiting NCT NCT07779343

    OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme

    Not yet reported University of Health Sciences, Algeria 300 participants Est. completion 2028-01-23 1 site Added to GLP-1
    Type 2 diabetes Other conditions: Obesity Difficult Airway Airway Management, Obesity Adult Onset, Obesity and Cardiovascular Risk
    View official trial listing →
  • Active, not recruiting NCT NCT05067621

    Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

    Not yet reported Yale University 60 participants Est. completion 2027-01 1 site
    Type 2 diabetesPrediabetes Other conditions: Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
    View official trial listing →
  • Withdrawn NCT NCT05812183

    Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity

    Not yet reported University of California, Los Angeles Est. completion 2025-02-12
    Other conditions: Dyspnea, Quality of Life
    View official trial listing →
  • Completed NCT NCT05895643

    Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

    Not yet reported Psychiatric Centre Rigshospitalet 108 participants Est. completion 2025-07-31 1 site
    Alcohol use disorder Other conditions: Alcohol Abuse, Alcohol Addiction
    View official trial listing →
  • Enrolling by invitation NCT NCT07041983

    24-h Energy Expenditure and Anti-obesity Medication

    University of Pisa 30 participants Est. completion 2026-12-01 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT07216651

    WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

    Closed Loop Medicine 20 participants Est. completion 2026-03-18 1 site
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07282769

    Semaglutide (Wegovy) Treatment for Trichotillomania

    Not yet reported University of Chicago 10 participants Est. completion 2027-02
    Other conditions: Trichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder, Hair Pulling, Hair-Pulling Disorder
    View official trial listing →
  • Not yet recruiting NCT NCT07430059

    Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant

    Not yet reported Vivani Medical, Inc 20 participants Est. completion 2027-01
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07446998

    Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

    Not yet reported Veru Inc. 239 participants Est. completion 2027-12 13 sites Added to GLP-1
    Other conditions: Obesity & Overweight, Mobility Disability, HOMA-IR
    View official trial listing →
  • Not yet recruiting NCT NCT07462663

    SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer

    Not yet reported Hospital Universitari de Bellvitge 80 participants Est. completion 2035-01
    Other conditions: Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia, Endometrial Intraepithelial Neoplasia, Obesity & Overweight, BMI>40, Obesity, Obesity Grade III
    View official trial listing →
  • Not yet recruiting NCT NCT07621640

    Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)

    Not yet reported Hallym University 80 participants Est. completion 2031-02 2 sites
    Metabolic syndrome Other conditions: Obesity, Brown Adipose Tissue
    View official trial listing →
  • Not yet recruiting NCT NCT07797036

    Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes

    Not yet reported, Not yet reported University of Massachusetts, Worcester 226 participants Est. completion 2030-12-31 1 site Added to GLP-1
    Metabolic syndrome Other conditions: Gestational Diabetes Mellitus (GDM)
    View official trial listing →
  • Not yet recruiting NCT NCT07820358

    Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer

    Not yet reported The Methodist Hospital Research Institute 48 participants Est. completion 2031-12-31 4 sites Added to GLP-1
    Other conditions: Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer, Fertility-Sparing Treatment (FST), Obesity & Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Semaglutide (Wegovy), Semaglutide (Wegovy) weekly injection

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.